A detailed history of Tower Research Capital LLC (Trc) transactions in Longboard Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,039 shares of LBPH stock, worth $62,132. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,039
Previous 2,783 62.67%
Holding current value
$62,132
Previous $75,000 54.67%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$27.58 - $39.5 $48,099 - $68,888
-1,744 Reduced 62.67%
1,039 $34,000
Q2 2024

Aug 13, 2024

BUY
$17.0 - $27.03 $45,152 - $71,791
2,656 Added 2091.34%
2,783 $75,000
Q1 2024

May 15, 2024

SELL
$18.89 - $26.06 $28,882 - $39,845
-1,529 Reduced 92.33%
127 $2,000
Q4 2023

Feb 13, 2024

SELL
$3.68 - $6.5 $9,711 - $17,153
-2,639 Reduced 61.44%
1,656 $9,000
Q3 2023

Nov 14, 2023

BUY
$5.49 - $7.49 $20,719 - $28,267
3,774 Added 724.38%
4,295 $23,000
Q2 2023

Aug 14, 2023

SELL
$4.19 - $10.05 $10,542 - $25,285
-2,516 Reduced 82.84%
521 $3,000
Q1 2023

May 09, 2023

BUY
$3.84 - $5.96 $906 - $1,406
236 Added 8.43%
3,037 $12,000
Q4 2022

Feb 10, 2023

SELL
$2.95 - $5.5 $1,489 - $2,777
-505 Reduced 15.28%
2,801 $9,000
Q3 2022

Nov 10, 2022

BUY
$2.95 - $4.7 $472 - $752
160 Added 5.09%
3,306 $13,000
Q2 2022

Aug 15, 2022

BUY
$2.96 - $5.38 $8,637 - $15,698
2,918 Added 1279.82%
3,146 $10,000
Q1 2022

May 12, 2022

SELL
$4.0 - $6.0 $10,232 - $15,348
-2,558 Reduced 91.82%
228 $1,000
Q4 2021

Feb 14, 2022

BUY
$4.75 - $9.45 $9,661 - $19,221
2,034 Added 270.48%
2,786 $13,000
Q3 2021

Nov 15, 2021

BUY
$8.65 - $11.36 $6,176 - $8,111
714 Added 1878.95%
752 $6,000
Q2 2021

Aug 16, 2021

BUY
$7.95 - $17.3 $302 - $657
38 New
38 $0

Others Institutions Holding LBPH

About Longboard Pharmaceuticals, Inc.


  • Ticker LBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,586,000
  • Market Cap $812M
  • Description
  • Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...
More about LBPH
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.